- Email: [email protected]
5176994 Non-A, Non-B hepatitis virus genome RNA, CDNA and virus antigen protein
329
PATENT ABSTRACTS hibit increased levels of expression of HBcAg. Increased levels of expression is also achieved by various modifications of the HBcAg sequences.
5175273 NUCLEIC
ACID INTERCALATING AGENTS
Norbert Bischofberger, Mark D Matteucci assigned to Genentech Inc Pyridinone or pyrimidinone nucleoside bases containing fused aromatic polycyclic rings are provided. These polycyclic nucleosides are incorporated into oligonucleotides and hybridized to complementary nucleic acid. Fluorescence spectroscopy and thermal denaturation profiles provided evidence that the polycyclic base is intercalated into the resulting duplex. The fused polycyclic ring systems optionally are substituted with reactive species which inactivate complementary nucleic acids. The oligonucleotides of this invention are useful as improved probes, diagnostic reagents, or for cleaving or derivatizing predetermined domains within nucleic acids.
prostatic hyperplasia or hypertrophy in said transgenic mouse, said gene being introduced into the mouse, or an ancestor of the mouse, at an embryonic stage. 5175384 TRANSGENIC MICE DEPLETED IN MATURE T-CELLS AND METHODS FOR MAKING TRANSGENIC MICE Paulus J A Krimpenfort, Antonius J M Berns, Amsterdam, Netherlands assigned to GenPharm International Transgenic mice having a phenotype characterized by the substantial absence of mature T lymphocytes otherwise naturally occurring in said mice. The phenotype is conferred in the transgenic mouse by a transgene contained in at least the precursor stem cell of the T lymphocyte which is depleted. The transgene comprises a DNA sequence encoding a T cell receptor polypeptide variant which inhibits maturation of the T lymphocyte. 5175385
5175274 THERAPEUTIC
NUCLEOSIDES
Joe Van Tuttle, Thomas A Krenitsky assigned to Burroughs Wellcome Co This invention relates to certain 2'-fluoro nucleosides and pharmaceutically acceptable derivatives thereof and their use in the treatment of HIV infections. Also provided are pharmaceutical formulations and processes for the production of the compounds according to the invention.
5175383 ANIMAL MODEL FOR BENIGN PROSTATIC DISEASE Philip Leder, William J Muller assigned to President and Fellows of Harvard College A male transgenic mouse containing germ cells and somatic cells which contain a recombinant gene which is a vertebrate gene in the int-2/FGF family which is capable of promoting benign
VIRUS-RESISTANT TRANSGENIC MICE Thomas E Wagner, Xiao-Zhu Chen assigned to Ohio University/Edison Animal Biotechnolgy Center A transgenic mouse with enhanced viral resistance transmissible to its offspring is prepared by introduction of a gene encoding a human interferon having antiviral activity into a host mouse. The gene encodes the interferon of a different animal species and therefore its expression product is less toxic to the host at an embryonic, fetal, neonatal or junvenile stage of development. Preferably, the human beta interferon gene is introduced into the cells of a mouse. 5176994 NON-A, NON-B HEPATITIS VIRUS GENOME RNA, CDNA AND VIRUS ANTIGEN PROTEIN Shunji Mishiro, Tetsuo Nakamura, Tokyo, Japan assigned to Immuno Japan Inc
330
PATENTABSTRACTS
Non-A, Non-B Hepatitis Virus Genome RNA is disclosed along with cDNA and Virus Antigen Protein.
5176996 METHOD FOR MAKING SYNTHETIC OLIGONUCLEOTIDES WHICH BIND SPECIFICALLY TO TARGET SITES ON DUPLEX DNA MOLECULES, BY FORMING A COLINEAR TRIPLEX, THE SYNTHETIC OLIGONUCLEOTIDES AND METHODS OF USE Michael E Hogan, Donald J Kessler assigned to Baylor College of Medicine A method for making synthetic oligonucleotides which bind to target sequences in a duplex D N A forming colinear triplexes by binding to the major groove. The method includes scanning genomic duplex D N A and identifying nucleotide target sequences of greater than about 20 nucleotides having either about at least 65% purine bases or about at least 65% pyrimidine bases; and synthesizing synthetic oligonucleotides complementary to identified target sequences. The synthetic oligonucleotides have a G when the complementary location in the DNA duplex has a GC base pair and have a T when the complementary location in the DNA duplex has an AT base pair. The synthetic oligonucleotides are oriented 5' to 4' and bind parallel or 3' to 5' and bind anti-parallel to the about at least 65% purine strand.
5177010 PROCESS FOR TRANSFORMING CORN AND THE PRODUCTS THEREOF Stephen L Goldman, Anne C F Graves assigned to University of Toledo A method of producing transformed corn comprising making a wound in a corn seedling in an area of the corn seedling containing rapidly dividing cells and inoculating the wound with vir+ Agrobacterium tumefaciens. Also, this same method wherein the vir+ A. tumefaciens contains a vector comprising geneticallyengineered T-DNA. There are further provided a transformed corn pollen grain, a corn pollen grain produced by a plant grown from a seedling infected with vir + A. tumefaciens, a corn pollen grain produced by a plant grown from a seedling infected with vir degrees A. tumefaciens containing a vector comprising genetricallyengineered T-DNA, a corn pollen grain whose cells contain a segment of T-DNA, and corn derived from each of these pollen grains. There are also provided a transformed corn plant, a transformed corn plant derived from a corn seedling infected with vir+ Agrobacterium tumefaciens, a transformed corn plant derived from a corn seedling infected with vir+ A. tumefaciens containing a vector comprising genetically-engineered T-DNA, and a corn plant whose cells contain a segment of T-DNA. Finally, there are provided transformed corn derived from a corn seeding infected with vir+ Agrobacterium tumefaciens, and transformed corn derived from a corn seedling infected with vir+ A. tumefaciens containing a vector comprising genetically-engineered T-DNA.
5177011 5176997 DNA PROBE FOR MALE INFERTILITY Michael G Humphreys-Beher assigned to University of Florida The subject invention pertains to a novel means of identifying male infertility. The novel method involves the identification of a unique restriction enzyme digestion pattern which is highly specific to individuals with male sperm binding infertility.
PLANT ELONGATION FACTOR PROMOTERS, CODING SEQUENCES AND USES Christine Shewmaker, William R Hiatt, Ann R Pokalsky assigned to Calgene Inc Expression constructs are provided employing a plant EF-I alpha promote which allows for elevated expression in rapidly dividing cells. Sequences from the gene and untranslated regions associated with the gene may be employed in an antisense construct to reduce growth rate. The promoter finds particular use in protecting
PATENT ABSTRACTS hibit increased levels of expression of HBcAg. Increased levels of expression is also achieved by various modifications of the HBcAg sequences.
5175273 NUCLEIC
ACID INTERCALATING AGENTS
Norbert Bischofberger, Mark D Matteucci assigned to Genentech Inc Pyridinone or pyrimidinone nucleoside bases containing fused aromatic polycyclic rings are provided. These polycyclic nucleosides are incorporated into oligonucleotides and hybridized to complementary nucleic acid. Fluorescence spectroscopy and thermal denaturation profiles provided evidence that the polycyclic base is intercalated into the resulting duplex. The fused polycyclic ring systems optionally are substituted with reactive species which inactivate complementary nucleic acids. The oligonucleotides of this invention are useful as improved probes, diagnostic reagents, or for cleaving or derivatizing predetermined domains within nucleic acids.
prostatic hyperplasia or hypertrophy in said transgenic mouse, said gene being introduced into the mouse, or an ancestor of the mouse, at an embryonic stage. 5175384 TRANSGENIC MICE DEPLETED IN MATURE T-CELLS AND METHODS FOR MAKING TRANSGENIC MICE Paulus J A Krimpenfort, Antonius J M Berns, Amsterdam, Netherlands assigned to GenPharm International Transgenic mice having a phenotype characterized by the substantial absence of mature T lymphocytes otherwise naturally occurring in said mice. The phenotype is conferred in the transgenic mouse by a transgene contained in at least the precursor stem cell of the T lymphocyte which is depleted. The transgene comprises a DNA sequence encoding a T cell receptor polypeptide variant which inhibits maturation of the T lymphocyte. 5175385
5175274 THERAPEUTIC
NUCLEOSIDES
Joe Van Tuttle, Thomas A Krenitsky assigned to Burroughs Wellcome Co This invention relates to certain 2'-fluoro nucleosides and pharmaceutically acceptable derivatives thereof and their use in the treatment of HIV infections. Also provided are pharmaceutical formulations and processes for the production of the compounds according to the invention.
5175383 ANIMAL MODEL FOR BENIGN PROSTATIC DISEASE Philip Leder, William J Muller assigned to President and Fellows of Harvard College A male transgenic mouse containing germ cells and somatic cells which contain a recombinant gene which is a vertebrate gene in the int-2/FGF family which is capable of promoting benign
VIRUS-RESISTANT TRANSGENIC MICE Thomas E Wagner, Xiao-Zhu Chen assigned to Ohio University/Edison Animal Biotechnolgy Center A transgenic mouse with enhanced viral resistance transmissible to its offspring is prepared by introduction of a gene encoding a human interferon having antiviral activity into a host mouse. The gene encodes the interferon of a different animal species and therefore its expression product is less toxic to the host at an embryonic, fetal, neonatal or junvenile stage of development. Preferably, the human beta interferon gene is introduced into the cells of a mouse. 5176994 NON-A, NON-B HEPATITIS VIRUS GENOME RNA, CDNA AND VIRUS ANTIGEN PROTEIN Shunji Mishiro, Tetsuo Nakamura, Tokyo, Japan assigned to Immuno Japan Inc
330
PATENTABSTRACTS
Non-A, Non-B Hepatitis Virus Genome RNA is disclosed along with cDNA and Virus Antigen Protein.
5176996 METHOD FOR MAKING SYNTHETIC OLIGONUCLEOTIDES WHICH BIND SPECIFICALLY TO TARGET SITES ON DUPLEX DNA MOLECULES, BY FORMING A COLINEAR TRIPLEX, THE SYNTHETIC OLIGONUCLEOTIDES AND METHODS OF USE Michael E Hogan, Donald J Kessler assigned to Baylor College of Medicine A method for making synthetic oligonucleotides which bind to target sequences in a duplex D N A forming colinear triplexes by binding to the major groove. The method includes scanning genomic duplex D N A and identifying nucleotide target sequences of greater than about 20 nucleotides having either about at least 65% purine bases or about at least 65% pyrimidine bases; and synthesizing synthetic oligonucleotides complementary to identified target sequences. The synthetic oligonucleotides have a G when the complementary location in the DNA duplex has a GC base pair and have a T when the complementary location in the DNA duplex has an AT base pair. The synthetic oligonucleotides are oriented 5' to 4' and bind parallel or 3' to 5' and bind anti-parallel to the about at least 65% purine strand.
5177010 PROCESS FOR TRANSFORMING CORN AND THE PRODUCTS THEREOF Stephen L Goldman, Anne C F Graves assigned to University of Toledo A method of producing transformed corn comprising making a wound in a corn seedling in an area of the corn seedling containing rapidly dividing cells and inoculating the wound with vir+ Agrobacterium tumefaciens. Also, this same method wherein the vir+ A. tumefaciens contains a vector comprising geneticallyengineered T-DNA. There are further provided a transformed corn pollen grain, a corn pollen grain produced by a plant grown from a seedling infected with vir + A. tumefaciens, a corn pollen grain produced by a plant grown from a seedling infected with vir degrees A. tumefaciens containing a vector comprising genetricallyengineered T-DNA, a corn pollen grain whose cells contain a segment of T-DNA, and corn derived from each of these pollen grains. There are also provided a transformed corn plant, a transformed corn plant derived from a corn seedling infected with vir+ Agrobacterium tumefaciens, a transformed corn plant derived from a corn seedling infected with vir+ A. tumefaciens containing a vector comprising genetically-engineered T-DNA, and a corn plant whose cells contain a segment of T-DNA. Finally, there are provided transformed corn derived from a corn seeding infected with vir+ Agrobacterium tumefaciens, and transformed corn derived from a corn seedling infected with vir+ A. tumefaciens containing a vector comprising genetically-engineered T-DNA.
5177011 5176997 DNA PROBE FOR MALE INFERTILITY Michael G Humphreys-Beher assigned to University of Florida The subject invention pertains to a novel means of identifying male infertility. The novel method involves the identification of a unique restriction enzyme digestion pattern which is highly specific to individuals with male sperm binding infertility.
PLANT ELONGATION FACTOR PROMOTERS, CODING SEQUENCES AND USES Christine Shewmaker, William R Hiatt, Ann R Pokalsky assigned to Calgene Inc Expression constructs are provided employing a plant EF-I alpha promote which allows for elevated expression in rapidly dividing cells. Sequences from the gene and untranslated regions associated with the gene may be employed in an antisense construct to reduce growth rate. The promoter finds particular use in protecting